24/7 Patient Assistance: 760-405-8205

Lloyd Damon, MD

Medical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma

Hospitals & Clinics

  • Bio & Insurance Information

    Dr. Lloyd Damon is a board-certified medical oncologist based in San Francisco, California. He graduated from the University of Michigan Medical School and later did his residency in internal medicine at the UCSF. Dr. Damon has been practicing oncology for about 20 years and is currently associated with the UCSF Medical Center. He has also contributed to three research publications.



  • Education & Training

    dept_icon

    University of Michigan

    Medical School

    dept_icon

    UCSF

    Residency

  • Board Certifications

    American Board of Internal Medicine - Oncology

  • Hospital & Practice

    UCSF Medical Center

    Languages: English/Spanish

    (415) 353-1037

    505 Parnassus Ave

    San Francisco, California 94143

    Read More
  • Publications & Memberships

    Dr. Lloyd Damon has contributed to 3 publications.

    Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk Following Autologous Hematopoietic S...

    Mannis, G. N.,Martin, T. G.,Damon, L. E.,Andreadis, C.,Olin, R. L.,Kong, K. A.,Faham, M.,Hwang, J.,Ai, W. Z.,Gaensler, K. M.,Sayre, P. H.,Wolf, J. L.,Logan, A. C.; Biol. Blood Marrow Transplant.. 2016 Feb 24.

    See more >>

    Long-Term Outcomes of Patients with Intermediate-Risk Acute Myeloid Leukemia Treated with Autologous Hematopoietic Cell Transplant in First Complete Remission.

    Mannis, G. N.,Martin, T. G.,Damon, L. E.,Logan, A. C.,Olin, R. L.,Flanders, M. D.,Ai, W. Z.,Gaensler, K. M.,Kaplan, L. D.,Sayre, P. H.,Smith, C. C.,Wolf, J. L.,Andread...; Leuk. Lymphoma. 2015 Oct 23.

    See more >>

    Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, doubl...

    Ravandi, F.,Ritchie, E. K.,Sayar, H.,Lancet, J. E.,Craig, M. D.,Vey, N.,Strickland, S. A.,Schiller, G. J.,Jabbour, E.,Erba, H. P.,Pigneux, A.,Horst, H. A.,Recher, C.,K...; Lancet Oncol.. 2015 Aug 04.

    See more >>